Global measles vaccinations are nearly back to pre-pandemic levels, WHO report finds

The WHO annual measles assessment found roughly 11 million measles cases in 2024 (an 8% increase versus 2019) but an estimated 95,000 deaths (an 11% decline since 2019), reflecting shifts in where outbreaks occur. Global vaccination coverage is improving toward pre-pandemic levels — about 84% of children received at least one dose and 76% received two doses in 2024 — and WHO attributes nearly 59 million deaths averted to measles vaccination from 2000–2024. The report warns that rising outbreaks, including those that affected the US and prompted Canada to lose measles-free status, signal broader erosion in immunization programs, with cases increasingly concentrated in middle-income countries.

Analysis

Market structure: Near-term winners are established pediatric vaccine manufacturers (Merck MRK, GlaxoSmithKline GSK, Sanofi SNY) and diagnostics/logistics nodes (Abbott ABT, Danaher DHR, Thermo Fisher TMO, UPS) because catch‑up campaigns target the ~24% of annual birth cohorts missing a second dose (~140M births × 24% ≈ 34M additional second-dose opportunities/year). Pricing power will be limited — large volumes will flow through pooled buyers (Gavi/WHO) so revenue is volume-driven, not price-rich, favoring low-cost, high-capacity producers and integrated suppliers. losers include small-cap contract manufacturers and EM health budgets where fiscal strain may raise sovereign credit stress.

Risk assessment: Tail risks include a manufacturing contamination/recall (single-site disruption causing 6–12 month global supply squeeze), major reduction in Gavi/WHO funding (>15% cut) or politicized litigation/regulation increasing compliance costs. Time horizons: immediate (days) = media-driven volatility; short (3–12 months) = procurement tenders and catch‑up campaigns; long (1–3 years) = routine schedule restoration. Hidden dependencies: donor budgets, cold‑chain capacity and vaccine hesitancy trends that can mute demand despite supply availability.

Trade implications: Tactical trades favor durable large-cap pharma and diagnostics: accumulate MRK/GSK on dips as proxies for guaranteed procurement flows, add ABT/DHR for testing demand; use logistics exposure (UPS) as low-beta play on distribution volumes. Options: buy limited-cost call spreads on MRK/GSK 6–12 month expiries to leverage tender wins; size exposure modestly given procurement transparency. Rotate modest allocation (2–4% NAV) away from EM discretionary and travel exposure into healthcare suppliers over next 3–12 months.

Contrarian angles: Consensus underestimates multi-year secular demand from catch-up and two‑dose normalization — if global two-dose coverage moves from 76% → 85% over 18–36 months incremental doses ≈ 12M–16M/year, favoring capacity owners. Counterpoint: buyers (Gavi/WHO) can steer volume to low‑price suppliers, capping margin upside; watch for single large contract awards that can transiently re‑rate a small-cap supplier. Historical parallel: polio/pneumococcal catch-up campaigns show supply winners are those with validated multi-site capacity, not highest-margin producers.

Key Decisions for Investors

• Establish a 2–3% NAV long position split 60/40 MRK (ticker: MRK) / GSK (ticker: GSK) within 30 days to capture expected 3–12 month procurement volume increases; trim / take profits if combined vaccine-related revenues fail to grow >5% QoQ over two consecutive quarters or if WHO/Gavi announce a >15% funding cut.
• Allocate 1–1.5% NAV long to diagnostics/logistics: ABT (Abbott) 0.75% and DHR (Danaher) 0.5% for test/assay and point‑of‑care demand; add 0.5% in UPS for distribution skew. Hold 6–12 months and sell if WHO weekly case counts fall >50% vs peak within 8 weeks.
• Buy a 0.5% NAV 6–12 month MRK call spread (buy ~5% OTM, sell ~15% OTM) to lever a vaccine tender win while capping premium. Close if MRK stock rises >20% or if no major procurement/contract announcements within 90 days.
• Reduce EM discretionary/travel exposure by 1–2% NAV (example: cut EEM/emerging-market consumer discretionary overweight) and redeploy into the healthcare names above; further reduce by another 1% if measles cases in any single EM country exceed 10,000 cumulative reported cases in a rolling 30‑day window (signal of fiscal/credit stress).